Premier Alternatives

Feldan Therapeutics

Quebec, Canada · Founded 2007 · Privately Held (backing)

Operator of a peptide-based intracellular delivery platform designed to enable access to therapeutic targets within cells for the treatment of serious diseases. Feldan Therapeutics is based in Quebec, Canada and was founded in 2007. Its last known valuation is $40.3 million. It has raised $39.2 million.

Last price · $/share
—
Implied valuation
$40.3M
Total raised
$39.2M
Last round
—

Feldan Therapeutics key facts

  • Operator of a peptide-based intracellular delivery platform designed to enable access to therapeutic targets within cells for the treatment of serious diseases.
  • Feldan Therapeutics’s last known valuation is $40.3M.
  • It has raised $39.2M; the latest was Later Stage VC ($23.3M) in Aug 2024.
  • Notable investors include Investissement Quebec, Fonds de solidarite FTQ, AQC Capital, Amgen Ventures, Anges Québec — 14 tracked in total.
  • Status: Privately Held (backing).
Free account
More of Feldan Therapeutics with a free account
  • ·The complete investor list: 14 names
  • ·Watch Feldan Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Feldan Therapeutics funding rounds

No rounds on record

No funding rounds for Feldan Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Feldan Therapeutics valuation

Feldan Therapeutics's last known valuation is $40.3 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

Feldan Therapeutics investors

14 investors are on record for Feldan Therapeutics, including Investissement Quebec, Fonds de solidarite FTQ, AQC Capital and Amgen Ventures.

About Feldan Therapeutics

Operator of a peptide-based intracellular delivery platform designed to enable access to therapeutic targets within cells for the treatment of serious diseases. The company offers a proprietary shuttle technology that facilitates safe, rapid, and efficient delivery of antisense oligonucleotides, enabling patients with skin and lung diseases to benefit from novel therapies that reach previously inaccessible intracellular targets.

Sector
Healthcare
HQ
Quebec, Canada
Founded
2007
Employees
43
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$40.3M

Feldan Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.